## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

SHIRE LLC and SHIRE US INC.,

Civil Action No. 1:15-cv-13909

Plaintiffs,

v.

ABHAI, LLC,

Defendant.

### PLAINTIFFS' REPLY CLAIM CONSTRUCTION BRIEF



## **TABLE OF CONTENTS**

I.	INTE	VTRODUCTION			
II.		LATERAL ESTOPPEL IS NOT APPLICABLE TO THE DISPUTED MS2			
III.	THE DISPUTED CLAIM TERMS				
	A.	The '096 Patent		4	
		1.	"delayed pulsed enteric release" / "delayed pulse enteric release" ('096 Patent, Claims 1, 2, 8, 18, 20)	4	
	B.	The	'148 Patent	7	
		1.	"a delayed enteric release dosage form that provides delayed release upon oral administration" ('148 Patent, Claims 1 and 12)	7	
		2.	"a plasma concentration versus time curve (ng/ml versus hours) having an area under the curve (AUC) of about 467 to about 714 ng hr/ml" ('148 Patent, Claim 1) and	8	
		3.	"said plasma concentration curve has a maximum concentration ( $C_{max}$ ) of about 22.5 to about 40 ng/ml" ('148 Patent, Claim 2)	10	
		4.	"peak plasma concentration" ('148 Patent, Claims 1 and 12)	11	
		5.	"a human individual" / " a human patient" ('148 Patent, Claim 1)	12	
IV	CON	ICI IISI	ION	15	



## **TABLE OF AUTHORITIES**

	Page(s)
Cases	
Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Cir. 2003)	3
Amgen, Inc. v. Hoffman-La Roche Ltd., 494 F. Supp. 2d 54 (D. Mass. 2007)	3
Braintree Labs., Inc. v. Novel Labs., Inc., 749 F.3d 1349 (Fed. Cir. 2014)	12, 13, 15
<i>Glycobiosciences Inc. v. Innocutis Holdings, LLC,</i> No. 12-1902, 2015 WL 7574749 (D.D.C. Nov. 25, 2015)	10
Kara Tech. Inc. v. Stamps.com Inc., 582 F.3d 1341 (Fed. Cir. 2009)	7
Kollmorgen Corp. v. Yaskawa Elec. Corp., 147 F. Supp. 2d 464 (W. Va. 2001)	3
Merck & Co. v. Teva Pharm. USA, 395 F.3d 1364 (Fed. Cir. 2005)	7
New Hampshire v. Maine, 532 U.S. 742 (2001)	4, 5
O2 Micro Int'l, Ltd. v. Beyond Innovation Tech. Co., 521 F.3d 1351 (Fed. Cir. 2008)	2
Pall Corp. v. Micron Separations, Inc., 66 F.3d 1211 (Fed. Cir. 1995)	10
Parker-Hannifin Corp. v. Baldwin Filters, Inc., 724 F. Supp. 2d 810 (N.D. Ohio 2010)	
Pure Fishing, Inc. v. Normark Corp., No. 10-2140, 2011 WL 5082339 (D.S.C. Oct. 26, 2011)	10
Regents of Univ. of Cal. v. Dakocytomation Cal., Inc., 517 F.3d 1364 (Fed. Cir. 2008)	2
Shire Labs. Inc. v. Impax Labs., Inc., Case No. 03-cv-1164 GMS (D. Del.)	1. 10



## Case 1:15-cv-13909-WGY Document 73 Filed 07/21/16 Page 4 of 21

Shire LLC v. Colony Pharms. et al., Case No. 1:07-cv-00718-CCB (D. Md.)	1
Shire LLC v. Amerigen Pharms. Ltd., Civ. A. No. 14-cv-6095 (D.N.J.)	
Shire, LLC v. Neos Therapeutics, Inc., Case. No. 3:13-cv-01452-N (N.D. Tex.)	1
Shire LLC v. Sandoz, Case No. 1:07-cv-00197-PAB-CAS (D. Col.)	1
Tandon Corp. v. Int'l Trade Comm'n, 831 F.2d 1017 (Fed. Cir. 1987)	7
Teva Pharm. USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015)	9
TM Patents, L.P. v. Int'l Bus. Mach. Corp., 72 F. Supp. 2d 370 (S.D.N.Y. 1999)	2
Other Authorities	
End D Civy D 54(b)	2



#### I. INTRODUCTION

Abhai's argument that this Court is bound by collateral estoppel to accept the constructions adopted by the District of New Jersey in the ongoing *Amerigen* litigation is wrong. The *Amerigen* case is still pending, and claim construction may well be refined before final judgment is entered. Moreover, the disputed terms have been construed multiple times in prior Hatch-Waxman litigations relating to Adderall XR®, and each Court has applied its own, different, set of claim constructions. *See Shire, LLC v. Neos Therapeutics, Inc.*, Case. No. 3:13-cv-01452-N, D.I. 69 (N.D. Tex. Mar. 20, 2014); *Shire LLC v. Sandoz*, Case No. 1:07-cv-00197-PAB-CAS, D.I. 169 (D. Col. Sept. 24, 2008); *Shire Labs. Inc. v. Impax Labs., Inc.*, Case No. 03-cv-1164 GMS, D.I. 119, 2005 WL 319983 (D. Del. Feb. 9, 2005) (the "*Impax* case" or "*Impax*"). At the end of the day, Abhai is merely cherry-picking the prior constructions it prefers. But no prior court's construction can override the claim language, specification, and prosecution history of the '148 and '096 Patents.

Apart from its flawed collateral estoppel arguments, Abhai's proposed constructions fail on the merits. The Court should reject Abhai's attempts to shape the claims to suit its non-infringement positions.



1

<sup>&</sup>lt;sup>1</sup> These previous constructions are in Appendices A and B to Shire's Preliminary Claim Construction Brief, D.I. 60 ("Op. Br."). The District of Maryland, in *Shire LLC v. Colony Pharm. et al.*, Case No. 1:07-cv-00718-CCB, also construed certain claims in its memorandum order on Colony's motion to summary judgment of noninfringement. *See* D.I. 109 (Feb. 1, 2008).

# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

